Your browser doesn't support javascript.
loading
Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities.
Mehra, Tarun; Dongre, Kanchan; Boesing, Maria; Frei, Patricia; Suenderhauf, Claudia; Zippelius, Alfred; Leuppi, Joerg D; Wicki, Andreas; Leuppi-Taegtmeyer, Anne B.
Affiliation
  • Mehra T; Department of Oncology, Medical University Clinic, Kantonsspital Baselland, Liestal, Switzerland.
  • Dongre K; Department of Oncology & Hematology, University Hospital Zürich, University of Zurich, Zürich, Switzerland.
  • Boesing M; Department of Clinical Pharmacology & Toxicology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Frei P; Department of Patient Safety, University Hospital Basel, Basel, Switzerland.
  • Suenderhauf C; Medical University Clinic, Kantonsspital Baselland, Liestal, Switzerland.
  • Zippelius A; Department of Clinical Pharmacology & Toxicology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Leuppi JD; Department of Clinical Pharmacology & Toxicology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Wicki A; Department of Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Leuppi-Taegtmeyer AB; Medical University Clinic, Kantonsspital Baselland, Liestal, Switzerland.
Cancer Med ; 12(11): 12253-12262, 2023 06.
Article in En | MEDLINE | ID: mdl-37084178

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Switzerland Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Switzerland Country of publication: United States